Mizuho Initiates Coverage On Karuna Therapeutics with Buy Rating, Announces $120 Price Target

Mizuho analyst Vamil Divan initiates coverage on Karuna Therapeutics (NASDAQ:KRTX) with a Buy rating and a $120 price target.

Benzinga · 02/06/2020 10:11

Mizuho analyst Vamil Divan initiates coverage on Karuna Therapeutics (NASDAQ:KRTX) with a Buy rating and a $120 price target.